Pius Lutaaya
ID:
|
AN EPIDEMIOLOGICAL SURVEILLANCE STUDY ON ANTI-MICROBIAL RESISTANCE TESTING FOR LEPROSY IN UGANDA
REFNo: HS3014ES
1. To identify the optimal laboratory diagnostic method for AMR for leprosy at NTRL Uganda
2. To estimate the burden of resistance among leprosy (new cases and relapses, treatment failures and patients who live in villages where PEP has been distributed
|
Uganda |
2023-10-04 21:53:28 |
2026-10-04 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Joshua Epuitai
ID: UNCST-2022-R009519
|
Assessment of Utilization of Clinical Simulation in Teaching and Learning among undergraduate students in Busitema University and Lira University
REFNo: HS3027ES
4. To determine utilization of simulation in the teaching among undergraduate students in Lira and Busitema University,3. To explore experiences of conducting simulation in an inter-professional health training among undergraduate students in Lira and Busitema University ,2. To investigate facilitators, and barriers to the use of simulation among faculty and clinical preceptors in Lira and Busitema University,1. To determine the experiences, perceptions, and acceptability regarding the use of simulation among undergraduate students in Lira and Busitema University,
|
Uganda |
2023-10-04 13:55:20 |
2026-10-04 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Letizia Atim Maria
ID:
|
Comparison of patient profiles between health professionals and non-health professionals at Butabika national referral Hospital; a retrospective chart review.
REFNo: HS3062ES
1. To describe the sociodemographic profile of health professionals admitted to Butabika National Referral Hospital as compared to non-health professionals.
2.To describe the clinical profile of health professionals admitted to Butabika national referral hospital as compared to non-health professionals.
|
Uganda |
2023-10-04 13:50:27 |
2026-10-04 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Jimmy Alemiga
ID: UNCST-2023-R007605
|
Intangible Resources and Competitive Advantage in Indigenous Family Owned Businesses in Uganda
REFNo: SS1945ES
To explain how post 1st indigenous FOBs conceptualize the notion of competitive advantage Kampala City Council Authority.,To explore how post 1st indigenous FOBs in Kampala City Council Authority strategically position themselves to attain competitive advantage.,To analyze the influence of organizational culture on competitive advantage for post 1st indigenous FOBs in Kampala City Council Authority. ,To access the effect of human resource practices on competitive advantage for post 1st indigenous FOBs in in Kampala City Council Authority. ,To examine the influence of corporate reputation on competitive advantage for post 1st indigenous FOBs in Kampala City Council Authority. ,The purpose of this study is to examine the contribution of intangible resources and competitive advantage for post 1st generation indigenous FOBs in Kampala City Council Authority. The focus of the study is CA measured by cost leadership, differentiation, and focus strategy (Porter, 1980). The intent is to provide both theoretical and empirical evidence in the RBV stream that exists in as far as understanding the specific contribution of IRs in achieving CA. ,
|
Uganda |
2023-10-04 13:48:55 |
2026-10-04 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Prudence Beinamaryo
ID: UNCST-2023-R007239
|
Efficacy of the combination ivermectin and albendazole vs albendazole alone in school-aged children infected with Trichuris trichiura: a randomized controlled trial
REFNo: HS3160ES
To evaluate the safety and tolerability of the ,To determine the CRs and ERRs of the study drugs (i.e. albendazole alone, albendazole-ivermectin) against Ascaris lumbricoides and hookworm in co-infected participants.,To determine the egg reduction rates (ERRs) of ivermectin/albendazole combination therapy compared to albendazole monotherapy against T. trichiura,To demonstrate that co-administered ivermectin (200 µg/kg) plus albendazole (400 mg) is superior to albendazole (400 mg) monotherapy in terms of CRs against T. trichiura infections assessed by Kato-Katz at 14-21 days post-treatment in individuals aged 6-12 years.,
|
Uganda |
2023-10-04 13:42:09 |
2026-10-04 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|